Compare Medpace Holdings Inc (MEDP) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Snowflake Inc — how do they compare? Medpace Holdings Inc trades at $528.29 (market cap $15.08B), while Snowflake Inc trades at $276.11 (market cap $95.09B). The key difference: Snowflake Inc is far larger — about 6.3× Medpace Holdings Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | SNOW | |
|---|---|---|
Market Cap | $15.08B | $95.09B |
Sector | Technology | Technology |
52-Week High | $620.59 | $280.16 |
52-Week Low | $308.88 | $121.11 |
Enterprise Value | $14.55B | $94.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Snowflake (SNOW) trades at $274.09, up 1.93% with bullish technical indicators and strong analyst support. The stock shows consistent earnings beats with Q1 2026 EPS of $0.39 exceeding expectations of $0.3193. Revenue growth remains robust at $3.63 billion in 2025, though the company continues to operate at a net loss of -$1.29 billion. Technical analysis indicates bullish momentum with current price near resistance at $274, while institutional sentiment remains positive with 81% buy ratings.
Snowflake presents a growth investment opportunity with accelerating AI Data Cloud adoption and 30% revenue growth targets, but faces significant execution risks from persistent losses and intense cloud competition. The consensus price target of $299.58 suggests 9% upside potential, though profitability challenges and high valuation multiples require careful monitoring of margin improvement trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
